Halogen-stabilized insulin
An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The halogenated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Halogen substitution-based stabilization of insulin may enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.
1. An insulin analogue comprising a B-chain polypeptide incorporating an ortho-mono-halogenated phenylalanine at position B24.
2. The insulin analogue of claim 1 , wherein the analogue is an analogue of a mammalian insulin.
3. The insulin analogue of claim 2 , wherein the analogue is an analogue of human insulin.
4. A method of lowering blood glucose in a patient in need thereof comprising administering a physiologically effective amount of an insulin analogue or a physiologically acceptable salt thereof to the patient, wherein the insulin analogue or a physiologically acceptable salt thereof contains a B-chain polypeptide incorporating an ortho-mono-halogenated phenylalanine at position B24.